title: Pharmacological Management of Gestational Diabetes Mellitus.
abstract: Gestational diabetes mellitus (GDM) is one of the most common morbidities complicating pregnancy, with short- and long-term consequences to the mothers, fetuses, and newborns. Management and treatment are aimed to achieve best possible glycemic control, while avoiding hypoglycemia and ensuring maternal and fetal safety. It involves behavioral modifications, nutrition and medications, if needed; concurrent with maternal and fetal surveillance for possible adverse outcomes. This review aims to elaborate on the pharmacological options for GDM therapy. We performed an extensive literature review of different available studies, published during the last 50 years, concerning pharmacological therapy for GDM, dealing with safety and efficacy, for both fetal and maternal morbidity consequences; as well as failure and success in establishing appropriate metabolic and glucose control. Oral medication therapy is a safe and effective treatment modality for GDM and in some circumstances may serve as first-line therapy when nutritional modifications fail. When oral agents fail to establish glucose control then insulin injections should be added. Determining the best oral therapy in inconclusive, although it seems that metformin is slightly superior to glyburide, in some aspects. As for parenteral therapy, all insulins listed in this article are considered both safe and effective for treatment of hyperglycemia during pregnancy. Importantly, a better safety profile, with similar efficacy is documented for most analogues. As GDM prevalence rises, there is a need for successful monitoring and treatment for patients. Caregivers should know the possible and available therapeutic options.
authors.affiliation: Helen Schneider's Hospital for Women, Rabin Medical Center, Petah-Tikva, 39 Zabotinski St., 49100, Petah-Tikva, Israel.|The Sackler Faculty of Medicine, Tel Aviv University, POB 39040, 6997801, Tel Aviv, Israel.
authors.forename: Riki
authors.initials: R
authors.lastname: Bergel
authors.affiliation: Helen Schneider's Hospital for Women, Rabin Medical Center, Petah-Tikva, 39 Zabotinski St., 49100, Petah-Tikva, Israel.|The Sackler Faculty of Medicine, Tel Aviv University, POB 39040, 6997801, Tel Aviv, Israel.
authors.forename: Eran
authors.initials: E
authors.lastname: Hadar
authors.affiliation: Helen Schneider's Hospital for Women, Rabin Medical Center, Petah-Tikva, 39 Zabotinski St., 49100, Petah-Tikva, Israel.|The Sackler Faculty of Medicine, Tel Aviv University, POB 39040, 6997801, Tel Aviv, Israel.
authors.forename: Yoel
authors.initials: Y
authors.lastname: Toledano
authors.affiliation: Helen Schneider's Hospital for Women, Rabin Medical Center, Petah-Tikva, 39 Zabotinski St., 49100, Petah-Tikva, Israel. hodroyal@inter.net.il.|The Sackler Faculty of Medicine, Tel Aviv University, POB 39040, 6997801, Tel Aviv, Israel. hodroyal@inter.net.il.
authors.forename: Moshe
authors.initials: M
authors.lastname: Hod
mesh_terms: D016640:Diabetes, Gestational / Q000188:drug therapy*; D005260:Female; D005905:Glyburide / Q000008:administration & dosage; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D011247:Pregnancy
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D005905:Glyburide
keywords: Gestational diabetes mellitus (GDM); Glyburide; Insulin; Metformin; Oral medication therapy